How was the Tdap booster vaccine tested for safety before approval? This page documents the pre-licensure clinical trial data for Boostrix and Adacel — including trial design, controls, and adverse events.
Clinical trial data for the two Tdap vaccines licensed for adolescents and adults in the US. Both Adacel (Sanofi) and Boostrix (GSK) were licensed in 2005 and both used Decavac (a Td vaccine, Sanofi) as their control. Decavac was not itself licensed via a placebo-controlled trial. Adacel contains dramatically less antigen than the infant DTaP formulation — 12.5× less diphtheria toxoid and 10× less pertussis toxin than Infanrix — because the full DTaP dose is too reactogenic in older recipients.
| Field | Value |
|---|---|
| Licensed | 2005 |
| Trial population | Not specified in source |
| Control group | Decavac (Td vaccine, Sanofi) — not licensed on placebo trial |
| Antigen vs. Infanrix DTaP | 12.5× less diphtheria toxoid; 10× less pertussis toxin |
Source: FDA-approved package insert; Sanofi licensure submission.
The dramatic reduction in antigen content was dictated by adverse reaction rates: the full DTaP antigen load used in infants causes too many adverse reactions in adolescents and adults. Adacel's weaker formulation was designed to reduce this reactogenicity while maintaining some immune response.
This raises a downstream question: if the higher antigen dose is too reactogenic for older bodies, why is it considered safe for the much smaller bodies of infants who receive the full Infanrix dose five times in the first six years of life?
| Field | Value |
|---|---|
| Licensed | 2005 |
| Trial population | Not specified in source |
| Control group | Decavac (Td vaccine, Sanofi) — not licensed on placebo trial |
Source: FDA-approved package insert; GSK licensure submission.
Boostrix (a GSK product) was licensed against Decavac (a Sanofi product) — the same control used for Adacel. Both products are "as safe as" Decavac. Decavac's own safety was not established through a placebo-controlled trial.
Decavac is a Td (tetanus-diphtheria) vaccine manufactured by Sanofi. It was not licensed on a placebo-controlled trial. The safety of both Tdap brands therefore traces back through Decavac to no validated baseline — consistent with the overall pattern across the schedule.
| Brand | Licensed | Control | Placebo? | Antigen vs. DTaP |
|---|---|---|---|---|
| Adacel (Sanofi) | 2005 | Decavac (Td) | NO | 12.5× less D / 10× less PT |
| Boostrix (GSK) | 2005 | Decavac (Td) | NO | Reduced |
| Population | Timing |
|---|---|
| Adolescents | 11–12 years (single dose) |
| Adults not previously vaccinated | Single dose Tdap, then Td every 10 years |
| Pregnant women | Each pregnancy (27–36 weeks gestation) |
| Caregivers of infants | Single dose if not previously vaccinated ("cocooning") |
Tetanus is environmental (soil exposure) and not person-to-person transmissible. Diphtheria has been functionally eradicated in the US for decades. Pertussis (whooping cough) continues to circulate in highly vaccinated populations because the vaccine does not prevent transmission. The adolescent Tdap booster was added because of waning immunity from childhood DTaP vaccination. The pregnancy Tdap recommendation aims to transfer maternal antibodies across the placenta to protect newborns in their first months of life.
Tdap Vaccines (Post-Licensure), Pre-Licensure Safety Testing, DTaP Vaccines (Pre-Licensure), Childhood Vaccine Schedule, Herd Immunity, Sanofi, GSK
Frequently Asked Questions